Business Context and Reporting Period
This Form 8-K Current Report was filed by Disc Medicine, Inc. (Nasdaq: IRON) on June 14, 2024. The filing announces the entry into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 4,944,000 shares of common stock.
- Offering Price: $36.00 per share.
- Expected Net Proceeds: Approximately $172.3 million (after underwriting discount and estimated offering expenses).
- Liquidity Outlook: Management expects cash and cash equivalents, combined with net proceeds, to fund operating and capital expenditure plans well into 2027.
- Closing Date: Expected on June 17, 2024, subject to customary closing conditions.
Material Changes
The filing does not provide comparative financial data (revenue, profit, or margins) as it is a current report regarding a specific corporate event rather than a periodic financial statement. The primary material change is the anticipated increase in liquidity and cash reserves resulting from the equity offering.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to use the proceeds to extend its runway for operations and capital expenditures through 2027. The offering is being conducted pursuant to a shelf registration statement (Form S-3) filed in November 2023.
Risks and Contingencies: The closing of the offering is subject to customary conditions. The Company has agreed to indemnify the underwriter against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing of the offering on or around June 17, 2024.
- Confirm the actual net proceeds received versus the estimated $172.3 million.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification terms.
- Monitor subsequent filings for the updated cash balance and any changes to the 2027 funding outlook.